Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
ConditionSolid Tumors
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-70
SponsorPeking University Cancer Hospital & Institute
About this trial
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Expected survival ≥ 12 weeks.
Good compliance with follow-up.
Presence of at least one measurable target lesion according to RECIST 1.1 criteria.
Female subjects must use effective contraception (effective contraception refers to sterilization, intrauterine hormone devices, condoms, contraceptive pills/agents, abstinence, or vasectomized partner) during the study and for 6 months after the study ends; male subjects must agree to use contraception during the study and for 6 months after the study ends.
Disqualifiers
Severe liver and kidney dysfunction.
Women preparing for pregnancy, pregnant, or breastfeeding.
Inability to lie flat for half an hour.
Inability to provide informed consent.
Trial population
Patients with pathologically confirmed newly diagnosed solid tumors
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
20 Participants
are grouped into 1 trial groupGroup A: solid tumor
Trial outcomes
Primary outcomes
1
To evaluate the diagnostic and staging accuracy of ⁸⁹Zr-s-C1 PET/CT imaging in patients with MUC18-positive solid tumors, particularly for lesions that remain indeterminate with conventional imaging modalities or ¹⁸F-FDG PET/CT.
SUVmax and SUVmean
Time frame
Imaging and analysis were performed 2, 24, and 48 hours after drug injection2
Measure the maximum standardized uptake value (SUVmax) of tumor lesions and compare it with that of surrounding normal tissues (such as the liver and muscles) to calculate the tumor-to-background ratio (TBR).
SUVmax and SUVmean
Time frame
Imaging and analysis were performed 2, 24, and 48 hours after drug injectionSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov